Develops small-molecule precision medicines for patients with neurological or psychiatric disorders.
10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 10, 2026
Competes with SK Life Science, UCB, Eisai, Xenon Pharmaceuticals, Biohaven, Praxis Precision Medicines, ES Therapeutics Australia, Supernus Pharmaceuticals, and Bristol Meyers Squibb
10-K for FY2025, filed Mar 10, 2026XCOPRI (cenobamate), which was developed by SK Life Science Inc. and approved by the FDA in November 2019; BRIVIACT (brivaracetam), which…View ↗
Loading...